In 1997 a sudden outbreak of visceral leishmaniasis (VL) occurred in eastern Sudan, coinciding with an increase of post-kala-azar dermal leishmaniasis (PKDL) cases which may in part be because of sylvatic and anthroponotic transmission. Paradoxically, the more VL patients are treated, the higher the frequency of PKDL. If PKDL plays a role in transmission, its treatment would be expected to reduce infection in the area. Treatment of PKDL, however, requires four times the amount of Pentostam used for treating VL, and the drug is both expensive and in short supply.
Post-kala-azar dermal leishmaniasis (PKDL) is a known complication of visceral leishmaniasis (VL) caused by Leishmania donovani and occurs with a frequency of 56% in patients treated for VL in Sudan. It is considered to be an important reservoir for this parasite in India (Thakur & Kumar 1992) and is strongly suspected to be so in some endemic foci in the Sudan (El Hassan et al. 1990 ). This is not surprising because L. donovani is found in skin lesions (Ismail et al. 1997) , and Phlebotomus orientalis, the vector for VL in Sudan, but not other man-biting sand¯ies in the endemic area could be successfully infected with the parasite when the¯ies were fed on PKDL lesions (Kirk & Lewis 1955) .
In 1990 members of the Leishmaniasis Research Group (LRG) at the University of Khartoum conducted a survey of VL and PKDL in an area known to be endemic for VL in eastern Sudan (population around 50 000). While no cases of VL were detected, 13 cases of PKDL were found in a cluster of hamlets and small villages in the area (El Hassan et al. 1990 ). In the following year (1991/1992) a crosssectional study in a village in the area showed the PKDL point prevalence to be 1.8%. Since 1991, cases of VL have been increasing steadily over the years. According to a statement by the Federal Minister of Health to the Sudanese parliament in 1998, a severe outbreak of VL took place in the area. Most of the 4000 cases reported occurred during 1997. In contrast, the number of VL cases recorded by the LRG during the period 1991±1996 was 492 cases. Because of its suddenness and magnitude, this dramatic increase is unlikely to have been because of the establishment of more accessible and better diagnostic facilities. The number of PKDL cases has also been increasing and in a cross-sectional survey we conducted in April 1996 in one village (Rugab, population 2000) , 95 cases of PKDL were found (point prevalence 4.8%). Most of these cases appeared within the last 3±5 years when treatment facilities were well established in the villages.
In the area of Malakal in southern Sudan, the Nile rat and some carnivores were found to be infected with L. donovani (Hoogstral & Heyneman 1969) . In Dinder National Park in eastern Sudan, where there are no human settlements, a high infection rate of P. orientalis with L. donovani was found, indicating the existence of an animal reservoir (Elnaeim et al. 1996) . Recently a group from Atbara River, eastern Sudan reported identi®cation of Leishmania from dogs (Dereure et al. 2000 ). It appears that there is sylvatic transmission and probably anthroponotic transmission in inhabited villages where no animal reservoir has been so far identi®ed with certainty (Mukhtar et al. 2000) .
Most PKDL cases never received antileishmanial treatment or were inadequately treated in the local dispensaries. As the pentavalent antimony compound, Pentostam (Wellcome Laboratories, London, UK), which is the standard treatment for both VL and PKDL in Sudan, is expensive and in short supply in the country, priority is given to treating the more serious VL which is fatal if not treated. Paradoxically, the more VL patients are treated, the higher the frequency of PKDL and hence the higher the probability of an increase in transmission of the parasite. Although some PKDL cases may self-cure in a relatively short period of time, in others PKDL remains for months or even years. One of our patients had PKDL for 10 years. If PKDL plays a role in transmission, its treatment would be expected to reduce infection in the area. Treatment of PKDL, however, requires four times the amount of Pentostam used for treating VL (WHO 1990) .
These observations raise some important questions regarding PKDL that need to be addressed. It is obvious that the present regimen recommended by WHO for treating VL (sodium stibogluconate 20 mg kg ±1 daily for 4 weeks) is ineffective in preventing the subsequent development of PKDL. It is not known if prolonging the treatment of VL with this drug or the use of other antileishmanial drugs would reduce the frequency of PKDL. Because the pathogenesis of PKDL remains obscure, more work is needed in this area if effective therapy and meaningful preventive measures are to be found for this important but rather neglected condition.
